dc.contributor.author | Pais, H | |
dc.contributor.author | Ruggero, K | |
dc.contributor.author | Zhang, J | |
dc.contributor.author | Al-Assar, O | |
dc.contributor.author | Bery, N | |
dc.contributor.author | Bhuller, R | |
dc.contributor.author | Weston, V | |
dc.contributor.author | Kearns, PR | |
dc.contributor.author | Mecucci, C | |
dc.contributor.author | Miller, A | |
dc.contributor.author | Rabbitts, TH | |
dc.date.accessioned | 2019-10-21T08:58:02Z | |
dc.date.issued | 2019-04-08 | |
dc.identifier.citation | Scientific reports, 2019, 9 (1), pp. 5760 - ? | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3383 | |
dc.identifier.eissn | 2045-2322 | |
dc.identifier.doi | 10.1038/s41598-019-42214-w | |
dc.description.abstract | The surfaceome is critical because surface proteins provide a gateway for internal signals and transfer of molecules into cells, and surfaceome differences can influence therapy response. We have used a surfaceome analysis method, based on comparing RNA-seq data between normal and abnormal cells (Surfaceome DataBase Mining or Surfaceome DBM), to identify sets of upregulated cell surface protein mRNAs in an LMO2-mediated T-ALL mouse model and corroborated by protein detection using antibodies. In this model the leukemia initiating cells (LICs) comprise pre-leukaemic, differentiation inhibited thymocytes allowing us to provide a profile of the LIC surfaceome in which GPR56, CD53 and CD59a are co-expressed with CD25. Implementation of cell surface interaction assays demonstrates fluid interaction of surface proteins and CD25 is only internalized when co-localized with other proteins. The Surfaceome DBM approach to analyse cancer cell surfaceomes is a way to find targetable surface biomarkers for clinical conditions where RNA-seq data from normal and abnormal cell are available. | |
dc.format | Electronic | |
dc.format.extent | 5760 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Cells, Cultured | |
dc.subject | Cell Membrane | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Mice | |
dc.subject | Adaptor Proteins, Signal Transducing | |
dc.subject | Receptors, G-Protein-Coupled | |
dc.subject | Proto-Oncogene Proteins | |
dc.subject | Interleukin-2 Receptor alpha Subunit | |
dc.subject | Leukemia, Lymphoid | |
dc.subject | Neoplastic Stem Cells | |
dc.subject | HEK293 Cells | |
dc.subject | LIM Domain Proteins | |
dc.subject | Transcriptome | |
dc.subject | Biomarkers, Tumor | |
dc.subject | CD59 Antigens | |
dc.subject | Tetraspanin 25 | |
dc.subject | RNA-Seq | |
dc.title | Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-03-27 | |
rioxxterms.versionofrecord | 10.1038/s41598-019-42214-w | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-04-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Scientific reports | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics | |
pubs.publication-status | Published | |
pubs.volume | 9 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Chromosomal Translocations and Intracellular Antibody Therapeutics | |
dc.contributor.icrauthor | Rabbitts, Terence | |